Cinzia Lanzi
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Targeting the heparan sulfate proteoglycan/heparanase axis as a novel therapeutic strategy to drive adipogenesis and block tumor growth of dedifferentiated liposarcoma.
Journal: International journal of biological sciences
Published: March 02, 2026
Editorial: Women in cancer molecular targets and therapeutics, volume II: 2022.
Journal: Frontiers in oncology
Published: June 17, 2023
Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers.
Journal: Frontiers in oncology
Published: June 09, 2022
Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas.
Journal: Biochemical pharmacology
Published: December 23, 2021
Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.
Journal: Journal of experimental & clinical cancer research : CR
Published: March 08, 2021
Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities.
Journal: Biochemical pharmacology
Published: April 27, 2020
Heparanase: A Potential Therapeutic Target in Sarcomas.
Journal: Advances in experimental medicine and biology
Published: April 11, 2020
Editorial: Heparan Sulfate Proteoglycans and Their Endogenous Modifying Enzymes: Cancer Players, Biomarkers and Therapeutic Targets.
Journal: Frontiers in oncology
Published: January 31, 2020
Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma.
Journal: Cancers
Published: February 05, 2019
Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity.
Journal: Molecules (Basel, Switzerland)
Published: October 08, 2018
Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases.
Journal: Cancer letters
Published: October 17, 2017
Last Updated: 09/26/2026